The Stanford Proteomic Shared Resource is a state-of-the-art proteomics facility dedicated to providingrapid and low-cost support for proteomic methods to Stanford Cancer Center investigators. Servicesinclude protein purification, peptide and protein identification, and analytical characterization ofmodifications and other small compounds. The Shared Resource has the necessary scientific andtechnical foundation, as well as a clean physical plant to conduct high accuracy mass spectrometry.Substantial cost savings, efficiency, and scientific advancement is provided by this type of centralizedfacility. An advisory board provides recommendations on facility policies and activities, ensuring thatthis Shared Resource is aligned with the Cancer Center's strategic goals. In fiscal year 2005, theProteomics Shared Resource has performed close to 600 proteomic analyses for 30 different laboratories,including 18 members of the Cancer Center, representing 6 of the 10 Cancer Center Programs. Use infiscal year 2005 reflected an increase of 60% as compared to 2004. Future plans for the Shared Resourceinclude expansion of capacity and capabilities with new mass spectrometers, an ongoing effort inimproved and novel analysis software, and development of chromatographic strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA124435-01
Application #
7438504
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-06-04
Project End
2010-05-31
Budget Start
2007-06-04
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$47,976
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications